April 3, 2019 07:00 AM EDTUpdated May 30, 11:22 AM

Editas and BlueRock join forces — and platform technologies — on a new wave of engineered cell therapies

John Carroll

Editor & Founder

Two prominent Boston-based biotechs are tying their platform technologies together to see how they can give each other a boost to their respective pipelines. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Editas and BlueRock join forces — and platform technologies — on a new wave of engineered cell therapies

John Carroll

Editor & Founder

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Is there still hope for Summit's cancer drug buried in the data?

MIT scientists’ AI model one-ups AlphaFold 3, takes on ‘fundamental issue’ in drug R&D

Biotech ranks as China’s best shot to surpass US in emerging tech, report finds

EMA considers serious eye condition a ‘very rare’ side effect of semaglutide

At a crossroads, biotechs are passing on reverse mergers in 2025

Cytiva and EurekaBio form strategic partnership to advance lentiviral vector manufacturing for cell and gene therapy ...

Ed­i­tas and Blue­Rock join forces — and plat­form tech­nolo­gies — on a new wave of en­gi­neered cell ther­a­pies

Editor & Founder

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Editas and BlueRock join forces — and platform technologies — on a new wave of engineered cell therapies